antipyrine has been researched along with cilostazol in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Koizumi, T; Morii, F; Nagakane, Y; Ohara, T; Tanaka, E; Yamamoto, Y | 1 |
Yamamoto, Y | 1 |
2 review(s) available for antipyrine and cilostazol
Article | Year |
---|---|
[Concept of branch atheromatous disease (BAD) and its clinical significance].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Edaravone; Humans; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Pipecolic Acids; Platelet Aggregation Inhibitors; Sulfonamides; Tetrazoles | 2010 |
[Concept, pathophysiology and treatment for branch atheromatous disease].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Clopidogrel; Contraindications; Drug Therapy, Combination; Edaravone; Humans; Magnetic Resonance Imaging; Pipecolic Acids; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Sulfonamides; Tetrazoles; Ticlopidine; Tissue Plasminogen Activator | 2014 |
1 other study(ies) available for antipyrine and cilostazol
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |